Therapy Name | GVAX colorectal cancer vaccine |
Therapy Description |
GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GVAX colorectal cancer vaccine | GVAX colorectal cancer vaccine is composed of irradiated colorectal cancer (CRC) cells engineered to express GM-CSF, which induces T-cell response against CRC cells (PMID: 24832153). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT01966289 | Phase I | Cyclophosphamide Guadecitabine GVAX colorectal cancer vaccine | SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) | Active, not recruiting |